SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Lepage, S.
Right arrow Articles by Chapman, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lepage, S.
Right arrow Articles by Chapman, M. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Oxidizability of Atherogenic Low-Density Lipoprotein Subspecies in Severe Familial Hypercholesterolemia: Impact of Long-Term Low-Density Lipoprotein Apheresis

Sylvie Lepage

Service de Biochimie, Hôpital de la Salpêtrière, Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière

Fabienne Nigon

Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière, Institut National de la Santé et de la Recherche Médicale

Dominique Bonnefont-Rousselot

Service de Biochimie, Hôpital de la Salpêtrière, Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière

Ubald Assogba

Centre Hémobiologie-Transfusion

Sylvie Goulinet

Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière, Institut National de la Santé et de la Recherche Médicale

Laurent Chancharme

Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière, Institut National de la Santé et de la Recherche Médicale

Jacques Delattre

Service de Biochimie, Hôpital de la Salpêtrière, Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière

Eric Bruckert

Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière, Service d'Endocrinologie-Métabolisme, Paris, France

M. John Chapman

Institut Fédératif de Recherche de Physiopathologie et de Génétique Cardiovasculaire, Centre Hospitalo-Universitaire de la Pitié-Salpêtrière, Institut National de la Santé et de la Recherche Médicale

Background: Oxidative modification of low-density lipoprotein (LDL) plays a key role in the pathophysiology of atherosclerosis. LDL-apheresis, which involves direct removal of plasma LDL from circulating blood, is an efficient treatment of homozygous familial hypercholes terolemia (FH).

Methods: We evaluated impact of long-term LDL apheresis treatment on the atherogenicity of the major LDL subclasses (light, LDL1, and LDL2, density [d] 1.018-1.030 g/mL; inter mediate, LDL3, d 1.030-1.040 g/mL, and dense LDL, LDL4 and LDL5, d 1.040-1.065 g/mL) separated by density gradient ultracentrifugation in severe FH patients. Therefore, we compared the oxidative resistance as well as the chemical and physical properties of each LDL subpopulation in the FH group with those in the corresponding LDL subfractions from normocholesterolemic control subjects.

Results: Both intermediate and dense LDL subfractions were significantly more resistant to copper-mediated oxidation in FH patients treated regularly by LDL-apheresis than their counterpart controls. The lag phases for LDL3, LDL4, and LDL5: 63.9 ± 1 1.6, 55.8 ± 1.2, and 47.2 ± 6.5 min. in FH patients were significantly longer than those of the corresponding subfractions in normocholesterolemic controls (P < .01 for LDL3 and LDL5, P < .005 for LDL4). This protective effect was reflected in the delayed formation of biologically active lipid oxidation products such as oxysterols, lipid hydroperoxides, dienes, and dienals in the intermediate and dense LDL subfractions of FH patients. These findings may result from lower "seed" contents of lipid hydroperoxide (LOOH) detected as dienes in plasma LDL from apheresis-treated FH patients; indeed, baseline LOOH/diene contents in all 5 LDL subclasses from FH patients were significantly lower than those of the corresponding subclasses in normolipidemic subjects (P < .0005). On the other hand, the enhanced oxidative resistance of both intermediate (LDL3) and dense (LDL4 and LDL5) LDL subpopulations in FH patients could not be accounted for by any consistent modification in chemical composition or in lipophilic antioxidant content, although minor differences were observed between patients and controls in unsaturated fatty acid profile. In contrast, sphingomyelin content was enriched in FH LDL subclasses, potentially resulting in reduced penetration of the hydrophilic surface layer of LDL by oxygen radicals.

Conclusion: We conclude that low concentrations of preformed lipid hydroperoxides and dienes, together with surface sphingomyelin enrichment, can account for the enhanced oxi dative resistance of intermediate (LDL3) and atherogenic dense LDL (LDL4, LDL5) induced by long-term LDL apheresis in severe FH patients.

Key Words: atherosclerosis • small dense LDL • polyunsaturated fatty acids • lipid hydroperoxides.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 5, No. 2, 87-103 (2000)
DOI: 10.1053/XV.2000.5588


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement